As of April 25, 2022, Mauritius was the African country with the highest number of coronavirus (COVID-19) doses secured per capita. The country had received **** COVID-19 vaccine doses per capita through bilateral agreements, donations, and the COVAX initiative. Seychelles and Rwanda followed with **** and **** doses per capita, respectively.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

BackgroundThe rapid development and rollout of COVID-19 vaccines helped reduce the pandemic’s mortality burden. The vaccine rollout, however, has been uneven; it is well known that vaccination rates tend to be lower in lower income countries. Vaccine uptake, however, ultimately depends on the willingness of individuals to get vaccinated. If vaccine confidence is low, then uptake will be low, regardless of country income level. We investigated the impact on country-level COVID-19 vaccination rates of both national income and vaccine hesitancy.MethodsWe estimated a linear regression model of COVID-19 vaccine uptake across 145 countries; this cross-sectional model was estimated at each of four time points: 6, 12, 18, and 24 months after the onset of global vaccine distribution. Vaccine uptake reflects the percentage of the population that had completed their primary vaccination series at the time point. Covariates include per capita GDP, an estimate of the percentage of country residents who strongly disagreed that vaccines are safe, and a variety of control variables. Next, we estimated these models of vaccine uptake by country income (countries below, and above the international median per capita GDP) to examine whether the impact of vaccine hesitancy varies by country income.ResultsWe find that GDP per capita has a pronounced impact on vaccine uptake at 6 months after global rollout. After controlling for other factors, there was a 22 percentage point difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by per capita GDP; this difference grew to 38% by 12 months. The deleterious impact of distrust of vaccine safety on vaccine uptake became apparent by 12 months and then increased over time. At 24 months, there was a 17% difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by distrust. The income stratified models reveal that the deleterious impact of vaccine distrust on vaccine uptake at 12 and 24 months is particularly evident in lower income countries.ConclusionsOur study highlights the important role of both national income and vaccine hesitancy in determining COVID-19 vaccine uptake globally. There is a need to increase the supply and distribution of pandemic vaccines to lower-income countries, and to take measures to improve vaccine confidence in these countries.

As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

Global Veterinary Vaccines Except for Foot and Mouth Market Size Value Per Capita by Country, 2023 Discover more data with ReportLinker!

COVID-19 Stats & Trends

Context

This dataset seeks to provide insights into what has changed due to policies aimed at combating COVID-19 and evaluate the changes in community activities and its relation to reduced confirmed cases of COVID-19. The reports chart movement trends, compared to an expected baseline, over time (from 2020/02/15 to 2020/02/05) by geography (across 133 countries), as well as some other stats about the country that might help explain the evolution of the disease.

Content

1. Grocery & Pharmacy: Mobility trends for places like grocery markets, food warehouses, farmers' markets, specialty food shops, drug stores, and pharmacies.
2. Parks: Mobility trends for places like national parks, public beaches, marinas, dog parks, plazas, and public gardens.
3. Residential: Mobility trends for places of residence.
4. Retail & Recreation: Mobility trends for places like restaurants, cafes, shopping centers, theme parks, museums, libraries, and movie theaters.
5. Transit stations: Mobility trends for places like public transport hubs such as subway, bus, and train stations.
6. Workplaces: Mobility trends for places of work.
7. Total Cases: Total number of people infected with the SARS-CoV-2.
8. Fatalities: Total number of deaths caused by CoV-19.
9. Government Response Stringency Index: Additive score of nine indicators of government response to CoV-19: School closures, workplace closures, cancellation of public events, public information campaigns, stay at home policies, restrictions on internal movement, international travel controls, testing policy, and contact tracing.
10. COVID-19 Testing: Total number of tests performed.
11. Total Vaccinations: Total number of shots given.
12. Total People Vaccinated: Total number of people given a shot.
13. Total People Fully Vaccinated: Total number of people fully vaccinated (might require two shots of some vaccines).
14. Population: Total number of inhabitants.
15. Population Density per km2: Number of human inhabitants per square kilometer.
16. Health System Index: Overall performance of the health system.
17. Human Development Index (HDI): Summary index based on life expectancy at birth, expected years of schooling for children and mean years of schooling for adults, and GNI per capita.
18. GDP (PPP) per capita: Gross Domestic Product (GDP) per capita based on Purchasing Power Parity (PPP), taking into account the relative cost of local goods, services and inflation rates of the country, rather than using international market exchange rates, which may distort the real differences in per capita income.
19. Elderly Population (percentage): Percentage of the population above the age of 65 years old.

References & Acknowledgements

Bing COVID-19 data. Available at: https://github.com/microsoft/Bing-COVID-19-Data COVID-19 Community Mobility Report. Available at: https://www.google.com/covid19/mobility/ COVID-19: Government Response Stringency Index. Available at: https://ourworldindata.org/grapher/covid-stringency-index Coronavirus (COVID-19) Testing. Available at: https://github.com/owid/covid-19-data/blob/master/public/data/testing/covid-testing-all-observations.csv Coronavirus (COVID-19) Vaccination. Available at: https://raw.githubusercontent.com/owid/covid-19-data/master/public/data/vaccinations/vaccinations.csv List of countries and dependencies by population. Available at: https://www.kaggle.com/tanuprabhu/population-by-country-2020 List of countries and dependencies by population density. Available at: https://www.kaggle.com/tanuprabhu/population-by-country-2020 List of countries by Human Development Index. Available at: http://hdr.undp.org/en/data Measuring Overall Health System Performance. Available at: https://www.who.int/healthinfo/paper30.pdf?ua=1 List of countries by GDP (PPP) per capita. Available at: https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD List of countries by age structure (65+). Available at: https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS

Authors

• Diogo Silva, up201706892@fe.up.pt

This study provides a macro-level societal and health system focused analysis of child vaccination rates in 30 European countries, exploring the effect of context on coverage. The importance of demography and health system attributes on health care delivery are recognized in other fields, but generally overlooked in vaccination. The analysis is based on correlating systematic data built up by the Models of Child Health Appraised (MOCHA) Project with data from international sources, so as to exploit a one-off opportunity to set the analysis within an overall integrated study of primary care services for children, and the learning opportunities of the ‘natural European laboratory’. The descriptive analysis shows an overall persistent variation of coverage across vaccines with no specific vaccination having a low rate in all the EU and EEA countries. However, contrasting with this, variation between total uptake per vaccine across Europe suggests that the challenge of low rates is related to country contexts of either policy, delivery, or public perceptions. Econometric analysis aiming to explore whether some population, policy and/or health system characteristics may influence vaccination uptake provides important results - GDP per capita and the level of the population’s higher education engagement are positively linked with higher vaccination coverage, whereas mandatory vaccination policy is related to lower uptake rates. The health system characteristics that have a significant positive effect are a cohesive management structure; a high nurse/doctor ratio; and use of practical care delivery reinforcements such as the home-based record and the presence of child components of e‑health strategies.

Summary statistics for outcome and explanatory variables.

Indonesia Average Monthly Expenditure per Capita: Goods and Services: Health Preventive Cost: Children Under-Fives Immunization Cost data was reported at 1,158.000 IDR in 2018. This records an increase from the previous number of 330.000 IDR for 2017. Indonesia Average Monthly Expenditure per Capita: Goods and Services: Health Preventive Cost: Children Under-Fives Immunization Cost data is updated yearly, averaging 92.500 IDR from Dec 2003 (Median) to 2018, with 16 observations. The data reached an all-time high of 1,158.000 IDR in 2018 and a record low of 18.000 IDR in 2003. Indonesia Average Monthly Expenditure per Capita: Goods and Services: Health Preventive Cost: Children Under-Fives Immunization Cost data remains active status in CEIC and is reported by Central Bureau of Statistics. The data is categorized under Indonesia Premium Database’s Domestic Trade and Household Survey – Table ID.HC001: Average Monthly Expenditure per Capita.

As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Context

The data is collected from OWID (Our World in Data) GitHub repository, which is updated on daily bases.

Content

This dataset contains only one file vaccinations.csv, which contains the records of vaccination doses received by people from all the countries. * location: name of the country (or region within a country). * iso_code: ISO 3166-1 alpha-3 – three-letter country codes. * date: date of the observation. * total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. * total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the country. * daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead. * daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. * daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the country. * people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. * people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the country. * people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. * people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the country.

Note: for people_vaccinated and people_fully_vaccinated we are dependent on the necessary data being made available, so we may not be able to make these metrics available for some countries.

Acknowledgements

This data collected by Our World in Data which gets updated daily on their Github.

Inspiration

Possible uses for this dataset could include: - Sentiment analysis in a variety of forms - Statistical analysis over time.

Context

To be honest it's pretty hard for you to find data on vaccine progress and especially time-based data on a country like Pakistan. So, I created this small but interactive notebook that will keep updating the database until everyone is vaccinated. In this project I have used Pandas for easy WebSracping to get the data from pharmaceutical-technology.com then I have created Sqlite3 database to store the data into three tables. It took me a few tries to get everything working smooth so I started using SQL queries to get the data and then used plotly to plot interactive visualization. I was not sure when they will update the website so, I have created few functions to avoid duplication of data and to inform me on telegram about updates. I have also uploaded the processed data to Kaggle from Deepnote which will be updated daily. At last, I have used the Deepnote Schedule notebook feature to run this notebook every day and successfully publishing the article You can find my work on Deepnote.

Content

• World_Vaccination_Progress.csv -> Countries Vaccination progress
• pakistan_time_series.csv -> Time series data of Pakistan vaccine progress
• world_time_series.csv -> Time series data of World vaccine progress

Columns: - Country :: Names of countries in the world - Doses Administered: Total Doses Administered - Doses per 1000 : Number of Doses per thousand - Fully Vaccinated Population (%) : Percentage of a fully vaccinated person in a country. - Vaccine being used in a country : Types of vaccines used in a country.

For Time-Series

• Date_Time : Timestamp of entry

Acknowledgements

I am thankful for Pharmaceutical Technology for updating the stats on daily basis and publicly provide real-time stats of world's vaccination drive. I also want to thank Deepnote for the introduction of the Schedule notebook feature that has made this automation possible.

Inspiration

The lack of data available in my country drove me to create an automated system that collects data from web. You can read more about it in my article. The second inspiration came from participating in Deepnote competition which was on the data Vaccination drive of your country or World.

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Context

This dataset provides State-by-state data on United States COVID-19 vaccinations between 20 December of 2020 and 12 January of 2022. Data is taken daily by the United States Centers for Disease Control and Prevention

Columns

us_vaccinations File

- location: State name.

- date: date of the case.

- total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again.

- total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the state.

- daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead.

- daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here.

- daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the state.

- people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

- people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the state.

- people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

- people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the state.

- total_distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System.

- total_distributed_per_hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state.

- share_doses_used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System.

Data as of: May 18, 2021

Preventive Vaccines Market Outlook

According to our latest research, the global preventive vaccines market size reached USD 54.8 billion in 2024, reflecting robust demand and sustained investments in immunization programs worldwide. The market is projected to expand at a CAGR of 7.1% from 2025 to 2033, with the market size forecasted to reach USD 102.3 billion by 2033. This impressive growth trajectory is underpinned by rising awareness of vaccine-preventable diseases, expanding immunization coverage, and the introduction of innovative vaccine technologies.

The growth of the preventive vaccines market is primarily driven by increasing government initiatives and funding for immunization programs across both developed and developing economies. The relentless global push for universal vaccination, particularly in response to recent pandemics and outbreaks, has galvanized public health agencies and non-governmental organizations to invest heavily in vaccine procurement and distribution. Additionally, the inclusion of new vaccines in national immunization schedules, such as those targeting HPV and hepatitis, has expanded the market’s scope significantly. The ongoing evolution of vaccine delivery mechanisms, such as needle-free systems and heat-stable formulations, has further improved accessibility and compliance, especially in remote and underserved populations. This ecosystem of innovation and investment continues to drive the market forward, ensuring that preventive vaccines remain a cornerstone of public health strategies worldwide.

Another critical growth factor is the rapid advancement in vaccine research and development, which has led to the introduction of next-generation vaccines with improved efficacy and safety profiles. The integration of cutting-edge technologies, including mRNA platforms and recombinant DNA techniques, has revolutionized the speed and precision with which new vaccines can be developed and deployed. This was particularly evident during the COVID-19 pandemic, where the expedited development and global distribution of vaccines set new benchmarks for the industry. Furthermore, increased private sector participation, strategic collaborations between pharmaceutical companies, and strong regulatory support have accelerated the approval and commercialization of novel vaccines. These advancements not only address emerging infectious diseases but also target non-communicable diseases, expanding the market’s potential applications and driving sustained growth.

The rising incidence of infectious diseases, coupled with heightened public awareness about the benefits of vaccination, is another major driver for the preventive vaccines market. Outbreaks of diseases such as influenza, measles, and polio continue to pose significant health threats, particularly in low- and middle-income countries. The global interconnectedness of populations has heightened the risk of rapid disease transmission, underscoring the importance of preventive vaccination as a first line of defense. Public health campaigns, educational initiatives, and social media outreach have played pivotal roles in dispelling vaccine hesitancy and misinformation, thereby improving vaccination rates. In addition, the growing geriatric population and increased prevalence of chronic diseases have broadened the target demographic for adult and elderly vaccines, further fueling market expansion.

Regionally, North America and Europe have traditionally dominated the preventive vaccines market due to their well-established healthcare infrastructure, high per capita healthcare spending, and comprehensive immunization programs. However, the Asia Pacific region is emerging as a significant growth engine, driven by rising healthcare investments, expanding population bases, and increasing government focus on public health. Countries such as China, India, and Japan are investing heavily in vaccine production capabilities and distribution networks to address both domestic and global demand. Latin America and the Middle East & Africa regions are also witnessing gradual improvements in vaccine coverage, supported by international aid and partnerships with global health organizations. Despite these advancements, disparities in access and affordability remain a challenge, particularly in resource-limited settings.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

Footnotes:aBirth data missing for Dominica, Kiribati, Palau, Marshall Islands, Seychelles, St. Kitts and Nevis, and Tuvalu and GDP data missing for Cuba, Democratic People's Republic of Korea, Marshall Islands, Myanmar, Somalia and Tuvalu.bAssumes that with tiered pricing the cost to vaccinate a child in upper-middle-income and DAC countries would also be 2.11% of GDP per capita.

IntroductionThe COVID-19 pandemic has resulted in numerous deaths, great suffering, and significant changes in people's lives worldwide. The introduction of the vaccines was a light in the darkness, but after 18 months, a great disparity in vaccination coverage between countries has been observed. As disparities in vaccination coverage have become a global public health issue, this study aimed to analyze several variables to identify possible determinants of COVID-19 vaccination.MethodsAn ecological study was conducted using pooled secondary data sourced from institutional sites. A total of 205 countries and territories worldwide were included. A total of 16 variables from different fields were considered to establish possible determinants of COVID-19 vaccination: sociodemographic, cultural, infrastructural, economic and political variables, and health system performance indicators. The percentage of the population vaccinated with at least one dose and the total doses administered per 100 residents on 15 June 2022 were identified as indicators of vaccine coverage and outcomes. Raw and adjusted values for delivered vaccine doses in the multivariate GLM were determined using R. The tested hypothesis (i.e., variables as determinants of COVID-19 vaccination) was formulated before data collection. The study protocol was registered with the grant number NCT05471635.ResultsGDP per capita [odds = 1.401 (1.299–1.511) CI 95%], access to electricity [odds = 1.625 (1.559–1.694) CI 95%], political stability, absence of violence/terrorism [odds = 1.334 (1.284–1.387) CI 95%], and civil liberties [odds = 0.888 (0.863–0.914) CI 95%] were strong determinants of COVID-19 vaccination. Several other variables displayed a statistically significant association with outcomes, although the associations were stronger for total doses administered per 100 residents. There was a substantial overlap between raw outcomes and their adjusted counterparts.DiscussionThis pioneering study is the first to analyze the association between several different categories of indicators and COVID-19 vaccination coverage in a wide complex setting, identifying strong determinants of vaccination coverage. Political decision-makers should consider these findings when organizing mass vaccination campaigns in a pandemic context to reduce inequalities between nations and to achieve a common good from a public health perspective.

The global vaccine glass bottle market is experiencing steady growth, driven by the increasing demand for vaccines globally. The market, valued at approximately $2.5 billion in 2025, is projected to exhibit a compound annual growth rate (CAGR) of 5% from 2025 to 2033. This growth is fueled by several factors, including rising vaccination rates worldwide, the ongoing development of new vaccines for emerging infectious diseases, and a growing preference for single-dose vials to minimize wastage and enhance safety. The increasing prevalence of chronic diseases requiring therapeutic vaccines further contributes to market expansion. Market segmentation reveals that the multi-dose segment currently holds a larger market share than the single-dose segment due to cost-effectiveness for mass vaccination programs. However, the single-dose segment is expected to witness faster growth driven by its advantages in preventing contamination and ensuring individual dosage accuracy. Within applications, preventive vaccines dominate the market share, mirroring the global focus on preventing infectious diseases. However, the therapeutic vaccine segment is expected to grow at a faster rate due to increased investment in the development of vaccines for treating chronic diseases like cancer. Key players such as Schott, Thermo Fisher Scientific, and Gerresheimer are leveraging their technological expertise to cater to the growing demands of the pharmaceutical industry, further fueling market expansion. Geographical analysis indicates that North America and Europe currently hold significant market shares, driven by robust healthcare infrastructure and high per capita vaccine consumption. However, Asia Pacific is projected to emerge as a high-growth region in the coming years due to rising disposable incomes, increasing healthcare expenditure, and expanding vaccination programs, particularly in countries like India and China. The market faces challenges such as stringent regulatory requirements for pharmaceutical packaging, intense competition among manufacturers, and potential fluctuations in raw material prices. Despite these challenges, the long-term outlook for the vaccine glass bottle market remains positive, driven by continuous innovation in vaccine technology and the global commitment to improving public health.

The global paediatric vaccine market is a dynamic sector characterized by significant growth driven by increasing immunization coverage rates, rising awareness of vaccine-preventable diseases, and the continuous development of new and improved vaccines. The market size in 2025 is estimated at $25 billion, projecting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This robust growth is fueled by several key factors. Firstly, government initiatives promoting vaccination programs in developing countries are significantly expanding market reach. Secondly, the emergence of novel vaccine technologies, such as mRNA vaccines, promises enhanced efficacy and safety profiles, stimulating further market expansion. Thirdly, increasing disposable incomes in many regions are making vaccines more accessible to families. However, challenges remain, including vaccine hesitancy, logistical hurdles in vaccine distribution, particularly in underserved regions, and the high cost of developing and manufacturing new vaccines. The market is segmented by vaccine type (e.g., live attenuated, inactivated), disease targeted (e.g., measles, polio, rotavirus), and distribution channel (e.g., hospitals, clinics). Major players such as GlaxoSmithKline, Merck, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Eli Lilly, Pfizer, F. Hoffmann-La Roche, and Novo Nordisk are actively engaged in research, development, and marketing of paediatric vaccines, driving intense competition and innovation within the sector. The forecast period from 2025 to 2033 indicates continued growth, though the rate may slightly modulate depending on the success of new vaccine introductions, evolving public health policies, and global economic conditions. Geographic distribution reveals a concentration of market share in developed regions like North America and Europe, initially, due to higher per capita income and established healthcare infrastructure. However, significant growth is anticipated in emerging markets driven by increasing government investments in public health programs and expanding access to healthcare services. Strategies employed by key players include strategic partnerships, acquisitions, and focused R&D efforts to broaden their vaccine portfolios and enhance market penetration. The long-term outlook remains positive, with continued advancements in vaccine technology and escalating demand pushing the paediatric vaccine market towards substantial expansion in the coming years.